Mile High Pd (DVA) is a medicare approved dialysis facility center in Lakewood, Colorado and it has 3 dialysis stations. It is located in Jefferson county at 1750 Pierce St Ste A, Lakewood, CO, 80214. You can reach out to the office of Mile High Pd (DVA) at (303) 232-0939. This dialysis clinic is managed and/or owned by Davita. Mile High Pd (DVA) has the following ownership type - Profit. It was first certified by medicare in August, 2002. The medicare id for this facility is 062541 and it accepts patients under medicare ESRD program.
| Name | Mile High Pd (DVA) |
|---|---|
| Location | 1750 Pierce St Ste A, Lakewood, Colorado |
| No. of Dialysis Stations | 3 |
| Medicare ID | 062541 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 1750 Pierce St Ste A, Lakewood, Colorado, 80214 | |
| (303) 232-0939 | |
| Not Available |
News Archive
Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.
A systematic review of HIV prevention, treatment and care for injecting drug users (IDUs) throughout the world, published Monday in the journal Lancet, found that international efforts to fight the disease are largely overlooking this population, the Australian Associated Press/Sydney Morning Herald reports (Rose, 3/1).
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.
Information on individuals' mobility-where they go as measured by their smartphones-has been used widely in devising and evaluating ways to respond to COVID-19, including how to target public health resources.
As the prevalence of maternal and fetal complications increases with advancing pregnancy beyond 39 weeks, induction of labor at 39 weeks has been proposed as a means to ensure optimal maternal and newborn health.
› Verified 4 days ago
| NPI Number | 1164890604 |
| Organization Name | Mile High Home Dialysis |
| Doing Business As | Kingston Dialysis Llc |
| Address | 1750 Pierce St Ste A Lakewood, Colorado, 80214 |
| Phone Number | (303) 232-0939 |
News Archive
Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.
A systematic review of HIV prevention, treatment and care for injecting drug users (IDUs) throughout the world, published Monday in the journal Lancet, found that international efforts to fight the disease are largely overlooking this population, the Australian Associated Press/Sydney Morning Herald reports (Rose, 3/1).
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.
Information on individuals' mobility-where they go as measured by their smartphones-has been used widely in devising and evaluating ways to respond to COVID-19, including how to target public health resources.
As the prevalence of maternal and fetal complications increases with advancing pregnancy beyond 39 weeks, induction of labor at 39 weeks has been proposed as a means to ensure optimal maternal and newborn health.
› Verified 4 days ago
| NPI Number | 1508026436 |
| Organization Name | Mile High Home Dialysis |
| Doing Business As | Mountain West Dialysis Services Llc |
| Address | 1750 Pierce St Lakewood, Colorado, 80214 |
| Phone Number | (303) 232-0939 |
News Archive
Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.
A systematic review of HIV prevention, treatment and care for injecting drug users (IDUs) throughout the world, published Monday in the journal Lancet, found that international efforts to fight the disease are largely overlooking this population, the Australian Associated Press/Sydney Morning Herald reports (Rose, 3/1).
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.
Information on individuals' mobility-where they go as measured by their smartphones-has been used widely in devising and evaluating ways to respond to COVID-19, including how to target public health resources.
As the prevalence of maternal and fetal complications increases with advancing pregnancy beyond 39 weeks, induction of labor at 39 weeks has been proposed as a means to ensure optimal maternal and newborn health.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 7 |
News Archive
Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.
A systematic review of HIV prevention, treatment and care for injecting drug users (IDUs) throughout the world, published Monday in the journal Lancet, found that international efforts to fight the disease are largely overlooking this population, the Australian Associated Press/Sydney Morning Herald reports (Rose, 3/1).
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.
Information on individuals' mobility-where they go as measured by their smartphones-has been used widely in devising and evaluating ways to respond to COVID-19, including how to target public health resources.
As the prevalence of maternal and fetal complications increases with advancing pregnancy beyond 39 weeks, induction of labor at 39 weeks has been proposed as a means to ensure optimal maternal and newborn health.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular peritoneal dialysis at the center | 40 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 333 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 94 |
| Pediatric patients getting regular peritoneal dialysis at the centre | 9 |
| Pediatric patient months included in Kt/V greater than or equal to 1.7 | 76 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.
A systematic review of HIV prevention, treatment and care for injecting drug users (IDUs) throughout the world, published Monday in the journal Lancet, found that international efforts to fight the disease are largely overlooking this population, the Australian Associated Press/Sydney Morning Herald reports (Rose, 3/1).
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.
Information on individuals' mobility-where they go as measured by their smartphones-has been used widely in devising and evaluating ways to respond to COVID-19, including how to target public health resources.
As the prevalence of maternal and fetal complications increases with advancing pregnancy beyond 39 weeks, induction of labor at 39 weeks has been proposed as a means to ensure optimal maternal and newborn health.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Mile High Pd (DVA) with elevated calcium levels.
| Patients with hypercalcemia | 40 |
| Hypercalcemia patient months | 331 |
| Patients with Serumphosphor | 43 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 21 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 23 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 25 |
| Patients with Serumphosphor greater than 7 mg/dL | 24 |
News Archive
Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.
A systematic review of HIV prevention, treatment and care for injecting drug users (IDUs) throughout the world, published Monday in the journal Lancet, found that international efforts to fight the disease are largely overlooking this population, the Australian Associated Press/Sydney Morning Herald reports (Rose, 3/1).
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.
Information on individuals' mobility-where they go as measured by their smartphones-has been used widely in devising and evaluating ways to respond to COVID-19, including how to target public health resources.
As the prevalence of maternal and fetal complications increases with advancing pregnancy beyond 39 weeks, induction of labor at 39 weeks has been proposed as a means to ensure optimal maternal and newborn health.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 31 |
| Hospitalization Rate in facility | 303.6 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 586 |
| Hospitalization Rate: Lower Confidence Limit | 165.6 |
News Archive
Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.
A systematic review of HIV prevention, treatment and care for injecting drug users (IDUs) throughout the world, published Monday in the journal Lancet, found that international efforts to fight the disease are largely overlooking this population, the Australian Associated Press/Sydney Morning Herald reports (Rose, 3/1).
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.
Information on individuals' mobility-where they go as measured by their smartphones-has been used widely in devising and evaluating ways to respond to COVID-19, including how to target public health resources.
As the prevalence of maternal and fetal complications increases with advancing pregnancy beyond 39 weeks, induction of labor at 39 weeks has been proposed as a means to ensure optimal maternal and newborn health.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Mile High Pd (DVA) were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 37.7 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 51.3 |
| Readmission Rate: Lower Confidence Limit | 25.5 |
News Archive
Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.
A systematic review of HIV prevention, treatment and care for injecting drug users (IDUs) throughout the world, published Monday in the journal Lancet, found that international efforts to fight the disease are largely overlooking this population, the Australian Associated Press/Sydney Morning Herald reports (Rose, 3/1).
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.
Information on individuals' mobility-where they go as measured by their smartphones-has been used widely in devising and evaluating ways to respond to COVID-19, including how to target public health resources.
As the prevalence of maternal and fetal complications increases with advancing pregnancy beyond 39 weeks, induction of labor at 39 weeks has been proposed as a means to ensure optimal maternal and newborn health.
› Verified 4 days ago